Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.
Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids. HNO. 2020 Jan 31;: Authors: Ferrone S, Whiteside TL Abstract This manuscript describes the functional properties of the exosomes released from melanoma cells. It details the characteristics of the tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4), which is used as a marker to separate exosomes released by melanoma cells from exosomes released by nonmalignant cells. The results are discussed in view of the potential role of melanoma cell-derived exosomes in the escape of malignant cells from the host's immune system. PMID: 32006045 [PubMed - as supplied by publisher]
ConclusionsImmunosuppressed patients who develop melanoma have worse outcomes when matched to non-immunosuppressed patients. This decrease in survival appears related to the underlying condition rather than diagnosis of melanoma.
Authors: Kim TH, Kim BR, Ko JS, Yoon JS PMID: 32233155 [PubMed - in process]
Immunotherapies harnessing T cell immunity have shown remarkable clinical success for the management of cancer. However, only a proportion of patients benefit from these treatments. The presence of type I interferon (IFN) within the tumor microenvironment is critical for driving effective tumor-specific T cell immunity. Individuals can produce 12 distinct subtypes of IFNα, which all signal through a common receptor. Despite reported differences in anti-viral potencies, the concept that distinct IFNα subtypes can improve anti-cancer treatments remains unclear. We tested whether expression of unique IFNα su...
ConclusionsResveratrol could synergistically enhance the killing effect of TK/GCV suicide gene system in melanoma B16 cells and transplanted melanoma. It might be a promising adjuvant of TK/GCV therapy.
Patients with malignant melanoma have a 5-year survival rate of only 15–20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for the majority of patients with melanoma harboring BRAFV600E mutation, over 90% of patients relapse within 2 years. Thus, there is a critical need for understanding MAPKi resistance mechanisms. In this manuscript, we performed a forward genetic screen using a whole genome shRNA library to identify negative regulators of vemurafenib resistance. We identified loss of NF1 and CUL3 as drivers of vemurafenib resistance. NF1 is ...
A new class of magnetite (Fe3O4) particles, coined as “Single Crystalline Micrometric Iron Oxide Particles” (SCMIOPs), were obtained by hydrothermal synthesis. Both the single Fe3O4 phase content and the particle sizes range, from 1 µm to 30 µm, can be controlled by synthesis. The notable finding states that these particles exhibit vanishing remanent magnetization (σr=0.28 emu/g) and coercive force (Hc=1.5 Oe), which indicate a superparamagnetic-like behavior (unexpected at micrometric particles size), and remarkably high saturation magnetization (σs=95.5 emu/g), what ensures strong magn...
Publication date: Available online 1 April 2020Source: International Journal of Surgery Case ReportsAuthor(s): Koichiro Kumano, Tsuyoshi Enomoto, Daichi Kitaguchi, Yohei Owada, Yusuke Ohara, Tatsuya Oda
Condition: Acral Melanoma Intervention: Drug: SHR-1210+Apatinib Sponsor: Di Wu Not yet recruiting
This article aims to present an extensive review of literature surrounding radiological surveillance in melanoma patients, a discussion of controversies, and recommendations for surveillance modalities. PMID: 32226349 [PubMed - in process]